Welcome to our dedicated page for DURECT news (Ticker: DRRX), a resource for investors and traders seeking the latest updates and insights on DURECT stock.
The DURECT Corporation (DRRX) news feed on Stock Titan aggregates historical company announcements, clinical updates, financial disclosures and transaction-related communications for this former Nasdaq-listed biopharmaceutical issuer. DURECT has described itself as a late-stage biopharmaceutical company focused on epigenetic therapies that target dysregulated DNA methylation, with particular emphasis on serious and life-threatening conditions such as alcohol-associated hepatitis (AH) and other forms of acute organ injury.
News items for DRRX include detailed updates on the development of the company’s lead investigational drug candidate, larsucosterol. These releases cover milestones such as the Phase 2b AHFIRM trial results, publication of data in NEJM Evidence, presentations at major liver disease meetings, and plans for a registrational Phase 3 trial in severe AH. Company communications also highlight that larsucosterol has received Fast Track and Breakthrough Therapy designations from the U.S. Food and Drug Administration for the treatment of AH.
The feed also captures DURECT’s corporate and portfolio developments, including announcements about its FDA-approved non-opioid analgesic POSIMIR, based on the SABER platform technology, and the sale of the ALZET osmotic pump product line. In 2025, a significant portion of the news flow relates to the tender offer and merger under which a subsidiary of Bausch Health Americas, Inc. agreed to acquire all outstanding shares of DURECT, followed by completion of the merger and subsequent delisting and deregistration of DRRX.
Investors and researchers can use this page to review historical earnings releases, business updates, clinical trial communications and acquisition-related announcements that together document DURECT’s evolution from a publicly traded company to an indirect wholly owned subsidiary within a larger pharmaceutical group.
DURECT Corporation (Nasdaq: DRRX) announced participation in a fireside chat at Oppenheimer's Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021. Key executives, including CEO James E. Brown and CFO Michael H. Arenberg, will engage in discussions highlighting the company’s strategies and clinical developments. The presentation will focus on DURECT's lead drug candidate, DUR-928, currently in a Phase 2b trial for alcohol-associated hepatitis, and its FDA-approved product, POSIMIR. The webcast can be accessed through DURECT's website, promoting transparency and investor engagement.
DURECT Corporation (Nasdaq: DRRX) announced participation in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. Management, including CEO James E. Brown and CFO Michael H. Arenberg, will discuss the company’s progress and strategies. A recording will be available on-demand starting at 7:00 A.M. ET on the same day. DURECT is advancing its lead drug candidate, DUR-928, for alcohol-associated hepatitis, with FDA Fast Track Designation, while its POSIMIR product is FDA-approved.
DURECT Corporation (Nasdaq: DRRX) reported Q2 2021 total revenues of $2.3 million with a net loss of $9.1 million, down from $24.5 million revenue and a net income of $14.3 million in Q2 2020.
They expanded U.S. clinical sites for the Phase 2b AHFIRM study of DUR-928 for severe alcohol-associated hepatitis. Future sites are planned in the UK, Europe, and Australia. DUR-928 shows promise in treating liver conditions, with Fast Track Designation from the FDA. Additionally, POSIMIR received FDA approval for post-surgical analgesia. Cash and investments rose to $88.6 million as of June 30, 2021.
DURECT Corporation (Nasdaq: DRRX) will disclose its second-quarter 2021 financial results and host a conference call on July 29, 2021, at 4:30 PM ET. The company is developing DUR-928, which aims to treat alcohol-associated hepatitis and has received Fast Track Designation from the FDA. Currently, they are conducting a Phase 2b clinical trial named AHFIRM. Additionally, the company's POSIMIR product has gained FDA approval. DURECT also cautions about risks related to clinical trials and commercialization.
DURECT Corporation (Nasdaq: DRRX) will present at the Epigenetic Therapeutic Targets Summit on July 15, 2021, discussing its lead drug candidate DUR-928 for alcohol-associated hepatitis. CEO James E. Brown will highlight positive Phase 2a results and provide details on the ongoing Phase 2b study with 300 hospitalized patients. DUR-928 acts as an epigenetic regulator, targeting DNA methylation to potentially improve cell survival and reduce inflammation in liver diseases. The presentation will be available on DURECT's website post-conference.
DURECT Corporation (Nasdaq: DRRX) presented new clinical data for DUR-928 at the 2021 International Liver Conference, showcasing potential efficacy in treating non-alcoholic steatohepatitis (NASH) and safety in subjects with hepatic impairment. The Phase 1b trial indicated a median 20% reduction in insulin resistance after 4 weeks of treatment. No adverse events were reported in the Phase 1 trial for hepatic impairment. DURECT is progressing with new trials and exploring additional applications for DUR-928.
DURECT Corporation (Nasdaq: DRRX) announced its participation at the International Liver Conference (EASL) from June 23-26, 2021, presenting two posters on DUR-928. The first poster highlights new efficacy signals from a Phase 1b study in nonalcoholic steatohepatitis (NASH) patients, showing improvements in liver health metrics. The second poster discusses a Phase 1 study on the safety and pharmacokinetics of DUR-928 in patients with varying hepatic impairments. Copies of the posters will be available on DURECT's website post-conference.
DURECT Corporation (DRRX) reported Q1 2021 financial results, achieving total revenues of $2.2 million and a net loss of $10.1 million, compared to $1.6 million and a net loss of $9.9 million in Q1 2020.
The company initiated patient dosing in the Phase 2b AHFIRM clinical study for DUR-928 in severe Alcohol-associated Hepatitis, while FDA approved POSIMIR for post-surgical analgesia. DURECT raised $47.8 million in equity, ending the quarter with $97.2 million in cash. Upcoming plans include discussions for POSIMIR commercialization and ongoing clinical trials.
DURECT Corporation (Nasdaq: DRRX) announced it will report its first quarter 2021 financial results on May 4, 2021, at 4:30 PM ET. The call will include a business update. The company is focused on developing innovative therapies for acute organ injuries and chronic liver diseases, notably its lead candidate DUR-928, which is currently in a Phase 2b trial for alcohol-associated hepatitis (AH). DURECT also has an FDA-approved product, POSIMIR, an analgesic solution. Risks associated with ongoing trials and commercialization efforts were highlighted in the release.
DURECT Corporation (Nasdaq: DRRX) published a peer-reviewed paper detailing the mechanism of action of its lead drug candidate, DUR-928, in The Journal of Lipid Research. DUR-928 acts as an epigenetic regulator, inhibiting DNA methyltransferases and regulating gene expression related to cellular activities. In clinical trials, DUR-928 demonstrated a 100% survival rate after 28 days in patients with alcohol-associated hepatitis (AH) and significant improvements in patients with non-alcoholic steatohepatitis (NASH). The company continues to advance ongoing clinical trials.
FAQ
What is the current stock price of DURECT (DRRX)?
What is the market cap of DURECT (DRRX)?
